Processa Pharmaceuticals Inc (PCSA)

Feb 21, 2025

The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl

Feb 21, 2025

Feb 21, 2025

Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions

Feb 21, 2025

Feb 21, 2025

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey

Feb 21, 2025

Feb 13, 2025

Processa Pharmaceuticals faces Nasdaq delisting risk over share price By Investing.com - Investing.com Nigeria

Feb 13, 2025

Feb 11, 2025

Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation - Defense World

Feb 11, 2025

Feb 10, 2025

Processa Pharmaceuticals faces Nasdaq delisting risk over share price - Investing.com

Feb 10, 2025

Feb 10, 2025

Processa Pharmaceuticals IncOn Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance - Marketscreener.com

Feb 10, 2025

Feb 10, 2025

Processa Pharmaceuticals Inc (PCSA) Shares Soar Above 1-Year High - The News Heater

Feb 10, 2025

Feb 07, 2025

Processa Pharmaceuticals to Present at 2025 BIO CEO & Investor Conference - Nasdaq

Feb 07, 2025

Feb 07, 2025

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire

Feb 07, 2025

Feb 07, 2025

Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan

Feb 07, 2025

Feb 06, 2025

Gastroparesis Market Expected to rise, 2034 | Vanda - openPR

Feb 06, 2025

Feb 03, 2025

Financial Analysis: Processa Pharmaceuticals Inc (PCSA)’s Ratios Unveil Key Insights - The Dwinnex

Feb 03, 2025

Jan 31, 2025

Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN

Jan 31, 2025

Jan 31, 2025

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

Jan 31, 2025

Jan 30, 2025

Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks

Jan 30, 2025

Jan 30, 2025

Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan

Jan 30, 2025

Jan 30, 2025

Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India

Jan 30, 2025

Jan 30, 2025

Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN

Jan 30, 2025

Jan 30, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 30, 2025

Jan 29, 2025

Processa Pharmaceuticals' chief business officer buys $34,691 in stock By Investing.com - Investing.com South Africa

Jan 29, 2025

Jan 29, 2025

Processa Pharmaceuticals director David Young buys $99,288 in stock By Investing.com - Investing.com South Africa

Jan 29, 2025

Jan 29, 2025

Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 By Investing.com - Investing.com UK

Jan 29, 2025

Jan 28, 2025

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire

Jan 28, 2025

Jan 28, 2025

Ulcerated Necrobiosis Lipoidica Market to Reach New Heights - openPR

Jan 28, 2025

Jan 28, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 By Investing.com - Investing.com Canada

Jan 28, 2025

Jan 28, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN

Jan 28, 2025

Jan 27, 2025

Processa CEO and Board Members Double Down: Major Insider Buying in Latest $5M Deal - StockTitan

Jan 27, 2025

Jan 21, 2025

Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance

Jan 21, 2025

Jan 19, 2025

PROCESSA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K) -June 09, 2021 at 01:17 pm EDT - Marketscreener.com

Jan 19, 2025

Jan 19, 2025

Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail

Jan 19, 2025

Jan 18, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.8 - MSN

Jan 18, 2025

Jan 17, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.8 By Investing.com - Investing.com South Africa

Jan 17, 2025

Jan 17, 2025

Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why - Defense World

Jan 17, 2025

Jan 16, 2025

Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail

Jan 16, 2025

Jan 11, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa

Jan 11, 2025

Jan 10, 2025

Processa Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com

Jan 10, 2025

Jan 09, 2025

Gastroparesis Treatment Market Future Business Opportunities - openPR

Jan 09, 2025

Jan 08, 2025

Trump Media & Technology Group Corp (DJT-Q) QuotePress Release - The Globe and Mail

Jan 08, 2025

Jan 06, 2025

Gastroparesis Treatment Market Investment Opportunities: A Guide to 2031 | Evoke Pharma, Inc., Processa - EIN News

Jan 06, 2025

Jan 03, 2025

Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews

Jan 03, 2025

Jan 02, 2025

BCE Inc (BCE-T) QuotePress Release - The Globe and Mail

Jan 02, 2025

Dec 31, 2024

Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews

Dec 31, 2024

Dec 20, 2024

Processa Pharmaceuticals stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia

Dec 20, 2024